Keyphrases
Anti-PD-1 Therapy
12%
Anti-programmed death-1 Therapy
12%
Antitumor Activity
62%
Autoreactive T Cells
12%
Cancer Cells
12%
Cancer Patients
15%
CD4+
12%
CD8+ T Cells
12%
Cell-to-cell
12%
Clinical Efficacy
12%
Clinical Potential
12%
Confidence Interval
37%
Effective Treatment
12%
First-in-class
12%
Immune Cells
12%
Immune Checkpoint Inhibitors
31%
Immune Modulatory Vaccine
78%
Immunogenicity
12%
Immunomodulating
12%
Immunosuppressive Cells
12%
Immunosuppressive Tumor
12%
Improved Survival
15%
Indoleamine 2,3-dioxygenase 1 (IDO1)
62%
Interleukin-6
62%
Interleukin-6 Signaling
62%
Median Overall Survival
12%
Median Progression-free Survival
12%
Metastatic Melanoma
62%
Monotherapy
12%
Murine Model
15%
Naïve Patients
12%
Nivolumab
62%
Objective Response Rate
12%
Pancreatic Cancer
62%
Patient Progress
12%
Phase 1/2 Study
12%
Programmed Death
62%
Programmed Death-ligand 1 (PD-L1)
25%
Radiotherapy
31%
Randomized Trial
12%
Safety Data
12%
Specific Immunity
15%
Specific Response
12%
Specific T Cells
62%
Systemic Toxicity
12%
T Cells
40%
Therapy-naïve
12%
Tumor Cells
12%
Tumor Site
12%
Vaccination
12%
Immunology and Microbiology
Adaptive Immune System
20%
Antineoplastic Activity
62%
Cancer Cell
12%
Cancer Immunotherapy
10%
Cell Infiltration
10%
Cytokine
52%
Cytotoxic T-Cell
12%
Immune Response
10%
Immunity
62%
Immunocompetent Cell
12%
Immunogenicity
12%
Immunosuppressive Drug
33%
Indoleamine 2,3-dioxygenase
62%
Interleukin 6
62%
Interleukin-6 Receptor
10%
Myeloid
10%
Nivolumab
62%
Overall Survival
12%
Preclinical Study
10%
Programmed Death 1 Ligand 1
12%
Progression Free Survival
12%
Receptor Antibody
10%
T Cell
100%
T-Helper Cell
12%
Tumor Cell
12%
Tumor-Associated Macrophage
10%
Vaccination Policy
12%
Vaccine Efficacy
62%
Medicine and Dentistry
Cytotoxic T-Cell
12%
Immunocompetent Cell
12%
Immunogenicity
12%
Immunosuppressive Drug
12%
In Vitro
12%
Indoleamine 2,3 Dioxygenase
62%
Malignant Neoplasm
12%
Metastatic Melanoma
62%
Monotherapy
12%
Neoplasm
12%
Nivolumab
62%
Overall Survival
12%
Programmed Death 1 Ligand 1
12%
Progression Free Survival
12%
T Cell
37%
T-Helper Cell
12%
Tumor Cell
12%